Score was significantly lower in the treatment group (3.3 ?1.4) than in the > 모바일_메인이미지

Score was significantly lower in the treatment group (3.3 ?1.4) than in the control group (4.9 ?1.8, p < 0.05, Figure 2). The DIC resolution rate was significantly higher in the treatment group (58.3 ) than in the control group on day 7 (26.1 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/14960617 p = 0.079,The 28-day mortality rate in the control group was 33.3 (8 of 23 patients) compared with 8.3 (1 of 12 patients) in the treatment group (p = 0.075 by Wilcoxon's test). We performed Cox regression analysis to adjust for the baseline variables of patients. We assessed a Boc-D-Lys-OH total of 11 possible confounders related to outcome: age, sex, APACHE II score, SOFA score, fulfilled ISTH criteria at the start of DIC treatment, AKI, ARDS, use of AT III, platelet concentrate, fresh frozen plasma, and administration of rhTM. Consequently, twoKato et al. Thrombosis Journal 2013, 11:3 http://www.thrombosisjournal.com/content/11/1/Page 5 of7 6 5 DIC score3 2 1 0 1 3Treatment group Control group*7 (days)Figure 2 Serial changes in the DIC score in the two groups. Data are expressed as group means ?standard deviation. The DIC score decreased over time in the treatment group (p < 0.05). The interaction between treatment and time was statistically significant (p < 0.01). The degree of decrease in the DIC score was significantly greater in the treatment group than in the control group. *p < 0.05 compared with the control group, p < 0.05 compared with baseline.prognostic variables were selected: AKI and administration of rhTM. After adjusting for AKI and rhTM administration was identified as an independent significant predictor of the probability of 28-day mortality (adjusted hazard ratio, 0.089 to 0.904; P = 0.026) (Table 2). The survival curves of the prediction model calculated by Cox regression analysis are shown PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/10572343 in Figure 4. Estimated survival showed higher in treatment group than control group. There was significant difference between the control and the treatment groups (p < 0.05). The SOFA score was not significantly different between the two100 90 80 DIC resolution rate, 70 60 50groups (Figure 5). In the coagulation tests, D-dimer level was significantly lower on day 7 (7.5 ?4.1 g/ml in the treatment group vs 30.9 ?33.6 g/ml in the control group; p < 0.01), while the platelet count, PT ratio, and fibrinogen levels were not significantly different at day 7 between the groups (Figure 6). AT III was used when the physician considered that it was required. AT III was administrated at a concentration of1500 IU per day for less than 3 days. AT III was not administrated after day 4. AT III activity was not significantly different at day 7 between the two groups, and showed a significantTreatment group20 10 0 1 2 3 4 5 6 7 (days) Control groupFigure 3 DIC resolution curves in Wilcoxon models. The solid line represents patients in the treatment group, and the dotted line represents patients in the control group. The DIC resolution rate increased over time in both groups. The DIC resolution rate was improved to a greater degree in the treatment group than in the control group (p = 0.079).Kato et al. Thrombosis Journal 2013, 11:3 http://www.thrombosisjournal.com/content/11/1/Page 6 ofTable 2 Independent variables in final 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol multiple regression models by Cox regression analysisVariables rhTM administration AKI Coefficient -0.958 0.840 Hazard ratio 0.384 2.316 95 CI 0.088 to 0.904 1.132 to 6.016 P value 0.026 0.rhTM, recombinant human soluble thrombomodulin; AKI, acute kidney injury; CI, confidence interval.differen.